… Given the multiple genetic etiologies for PD already identified, the marked variability in the
loss of dopaminergic markers measured by imaging at motor symptom onset and the well-…

Background Emerging evidence shows that α-synuclein seed amplification assays (SAAs)
have the potential to differentiate people with Parkinson's disease from healthy controls. We …

The loss of dopaminergic neurons in the substantia nigra pars compacta leads to the
characteristic motor symptoms of Parkinson's disease: bradykinesia, rigidity and resting tremors. …

Importance We observed a significant correlation between cerebrospinal fluid (CSF) levels
of tau proteins and α-synuclein, but not β-amyloid 1-42 (Aβ1-42), and lower concentration of …

Objective The Parkinson's Progression Markers Initiative ( PPMI ) is an observational,
international study designed to establish biomarker‐defined cohorts and identify clinical, imaging, …

Recessively inherited loss-of-function mutations in the PTEN-induced putative kinase 1(Pink1),
DJ-1 (Park7) and Parkin (Park2) genes are linked to familial cases of early-onset …

Multiple studies implicate metals in the pathophysiology of neurodegenerative diseases.
Disturbances in brain iron metabolism are linked with synucleinopathies. For example, in …

Background Accurate diagnosis and early detection of complex diseases, such as Parkinson's
disease, has the potential to be of great benefit for researchers and clinical practice. We …

The objective of this study was to evaluate the pathology time course of the LRRK2 knockout
rat model of Parkinson’s disease at 1-, 2-, 4-, 8-, 12-, and 16-months of age. The evaluation …

The development of biomarkers to predict the progression of Parkinson’s disease (PD) from
its earliest stage through its heterogeneous course is critical for research and therapeutic …